Related Experiment Video

Updated: Mar 13, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

6.7K

CaMKII as a target for arrhythmia suppression

Julian Mustroph1, Stefan Neef1, Lars S Maier1

  • 1Universitäres Herzzentrum Regensburg, Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Germany.

Pharmacology & Therapeutics
|October 16, 2016
PubMed

Insights

Calcium/calmodulin-dependent protein kinase II (CaMKII) is crucial in heart failure and arrhythmias. This review explores new anti-arrhythmic strategies targeting CaMKII and its related signaling pathways for clinical application.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Calcium/calmodulin-dependent protein kinase II (CaMKII) is implicated in cardiac pathologies like heart failure and arrhythmias.
  • CaMKII activation pathways are understood, but few clinical treatments exist.

Purpose of the Study:

  • To review recent advances in anti-arrhythmic strategies targeting CaMKII.
  • To discuss both direct CaMKII inhibition and indirect modulation via upstream/downstream signaling.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of CaMKII signaling pathways in cardiac pathophysiology.
  • Evaluation of potential therapeutic interventions for arrhythmias.

Main Results:

  • CaMKII plays a significant role in contractile dysfunction and arrhythmias.
  • Several strategies targeting CaMKII are under investigation.
  • Modulating upstream and downstream signaling offers alternative anti-arrhythmic approaches.

Conclusions:

  • Targeting CaMKII presents a promising avenue for novel anti-arrhythmic therapies.
  • Further research is needed to translate in vitro findings into clinical treatments.
  • Comprehensive strategies involving CaMKII modulation could improve outcomes in cardiac diseases.
Keywords:
ArrhythmiasCaMKIICalcium leakExcitation–contraction couplingInhibitors

More Related Videos

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.7K
Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts08:43

Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts

Published on: August 26, 2021

3.0K

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
2.5K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.9K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
563